HIV-1 Reverse Transcriptase Variants: Molecular Modeling of Y181C, V106A, L100I, and K103N Mutations with Nonnucleoside Inhibitors Using Monte Carlo Simulations in Combination with a Linear Response Method

References

• Larder, B. A., and Kemp, S. D. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science, 246, 1155–1158.
   PubMed Web of Science ®Google Scholar
• St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., and Larder, B. A. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science, 253, 1557–1559.
   PubMed Web of Science ®Google Scholar
• Richman, D. D. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol., 68, 1660–1666.
   PubMed Web of Science ®Google Scholar
• Zhang, D., Caliendo, A. M., Eron, J. J, DeVore, K. M., Kaplan, J. C., Hirsch, M. S., and D'auuila, R. T. (1994). Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 38, 282–287.
   Google Scholar
• Boyer, P. L., Ding, J., Arnold, E., and Hughes, S. H. (1994). Subunit specificity of mutations that confer resistance to nonucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 38, 1909–1914.
   PubMed Web of Science ®Google Scholar
• Boyer, P. L., Tantillo, C., Jacobo-Molina, A., Nanni, R. G., Ding, J., Arnold, E., and Hughes, S. H. (1994). Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci., USA, 91, 4882–4886.
   PubMed Web of Science ®Google Scholar
• Moermans, M., De Raeymaeker, M., Boeckx, I., Van den Broeck, R., Stoffels, P., De Brabander, M., De Cree, J., Hertogs, K., Pauwels. R., Staszewski, S., and Andries, K. (1995). Viro-logical analysis of HIV-1 isolates in patients treated with the non-nucleoside reverse transcriptase inhibitor R091767 (8-Cl TIBO). Abstracts of the Fourth International Workshop on HIV-1 Drug Resistance, Sardinia, Italy.
   Google Scholar
• Metropolis, N., and Ulam, S. (1949). The Monte Carlo method. J. Am. Stat. Assoc., 44, 335–341.
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L. (1998). MCPRO, Version 1.6. New Haven, CT: Yale University.
   Google Scholar
• Aqvist, J., Medina, C., and Samuelsson, J.-E. (1994). A new method for predicting binding affinity in computer-aided drug design. Prot. Eng., 7, 385–391.
   Google Scholar
• Carlson, H. A., and Jorgensen, W. L. (1995). An extended linear response method for determining free energies of hydration. J. Phys. Chem., 99, 10667–10673.
   Web of Science ®Google Scholar
• McDonald, N. A., Carlson, H. A., and Jorgensen, W. L. (1997). Free energies of solvation in choroform and water from a linear response approach. J. Phys. Org. Chem., 10, 563–576.
   Web of Science ®Google Scholar
• Hertzog-Jones, D. K., and Jorgensen W. L. (1997). Binding affinities for sulfoamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method. J. Med. Chem., 40, 1539–1549.
   PubMed Web of Science ®Google Scholar
• Lamb, M. L., and Jorgensen, W. L. (1999). Investigations of neurotropic inhibitors of FK506 binding protein via Monte Carlo simulations. J. Med. Chem., 41, 3928–3939.
   Web of Science ®Google Scholar
• Lamb, M. L., Tirado-Rives, J., and Jorgensen, W. L. (1999). Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. Bioorg. Med. Chem., 7, 851–860.
   PubMed Web of Science ®Google Scholar
• Pierce, A. C., and Jorgensen, W. L. (1997). Computational binding affinities for trypsin benzamidine complexes via free energy perturbations. J. Phys. Chem. B, 36, 1466–1469.
   Google Scholar
• Smith, R. H., Jr., Jorgensen, W. L., Tirado-Rives, J., Lamb, M. L., Janssen, P. A. J., Michejda, C. J., and Kroeger Smith, M. B. (1998). Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J. Med. Chem., 41, 5272- 5286.
   PubMed Web of Science ®Google Scholar
• Rizzo, R. C., Tirado-Rives, J., and Jorgensen, W. L. (2001). Estimation of binding affinities for HEPT and nevirapine analogs with HIV-1 reverse transcriptase via Monte Carlo simulations. J. Med. Chem., 44, 145–154.
   PubMed Web of Science ®Google Scholar
• Rizzo, R. C., Blagovic, M. U., Wang, D.-P., Watkins, E. K., Smith, M. B. K. K., Smith, R. H ., Jr., Tirado-Rives, J., and Jorgensen, W. L. (2002). Prediction of activity for nonnucleoside inhibitors with HIV reverse transcriptase based on Monte Carlo simulations. J. Med. Chem., 45, 2970–2987.
   PubMed Web of Science ®Google Scholar
• Kroeger Smith, M., Hose, B. M., Hawkins, A., Lipchock, J., Farnsworth, D. W., Rizzo, R. C., Tirado-Rives, Arnold, E., Zhang, W., Hughes, S. H., Jorgensen, W. L., Farnsworth, D. W., Michejda, C. J., and Smith, R. H., Jr. (2003). Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogs, J. Med. Chem., 46, 1940–1947.
   PubMed Web of Science ®Google Scholar
• Roth, T., Morningstar, M. L., Boyer, P. L., Hughes, S. H., Buckheit, R. W., Jr., and Michejda, C. J. (1997). Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J. Med. Chem., 40, 4199–4207.
   PubMed Web of Science ®Google Scholar
• Morningstar, M. L., Roth, T., Smith, M. Kroeger, Zajac, M., Watson, K., Buckheit, R. W., Jr., and Michejda, C. J. (2004). Synthesis and biological activity of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J. Med. Chem., to appear.
   Google Scholar
• Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P. A. J., Hughes, S. H., and Arnold, E. (1995). Structure of HIV-1 RT/TIBO R86183 complex reveals remarkable similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol., 2, 407–415.
   PubMedGoogle Scholar
• Kroeger Smith, M. B., Lamb, M. L., Tirado-Rives, J., Jorgensen, W. L., Michejda, C. J., Ruby, S. K., and Smith, R. H., Jr. (2000). Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor 8-Cl TIBO: Contribution of the L100I and Y181C variants to protein stability and biological activity. Prot. Eng., 13, 413- 421.
   Google Scholar
• Das, K., Ding, J., Hsiou, Y., Clark, A. D., Jr., Moereels, H., Koymans, L., Andries, K., Pauwels, R., Janssen, P. A. J., Boyer, P. D., Clark, P., Smith, R. H., Jr., Kroeger Smith, M. B., Michejda, C. J., Hughes, S. H., and Arnold, E. (1996). Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIVRT and 8-Cl TIBO complexed with the tyr181cys HIV-1 RT drug resistant mutant. J. Mol. Biol., 264, 1085–1100.
   PubMed Web of Science ®Google Scholar
• Kroeger Smith, et al., unpublished data.
   Google Scholar
• Jorgensen, W. L. (2003). Biochemical and Organic Model Builder (BOMB), Version 2.3, New Haven, CT: Yale University Press.
   Google Scholar
• Jorgensen, W. L., unpublished data.
   Google Scholar
• E. Arnold, Rutgers University, New Branswick, NJ, unpublished data.
   Google Scholar
• R. W. Buckheit, Jr., personal communication.
   Google Scholar
• Cheng, Y., and Prusoff, W. H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099–3108.
   PubMed Web of Science ®Google Scholar
• JMP-Jn, Version 4 (2001). SAS Institute Inc., Cary, NC.
   Google Scholar